Yao Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yao Lu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Haijiang Dai
Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 shared publications - Nicola Luigi Bragazzi
Department of Clinical Pharmacy, Saarland University, 66123 Saarbrücken, Germany
4 shared publications Haijiang Dai
Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China
2 shared publicationsJianhong Wu
Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China
2 shared publicationsZhiheng Chen
Department of Health Management, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China
2 shared publicationsAijun An
Department of Electrical Engineering and Computer Science, York University, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 11 February 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Global, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990–2017
Objective: To estimate the burden of myocarditis (MC), alcoholic cardiomyopathy (AC), and other cardiomyopathy (OC) for 195 countries and territories from 1990 to 2017.Methods: We collected detailed information on MC, AC, and OC between 1990 and 2017 from the Global Burden of Disease study 2017, which was designed to provide a systematic assessment of health loss due to diseases and injuries in 21 regions, covering 195 countries and territories. Estimates of MC, AC, and OC burden were produced using a standard Cause of Death Ensemble model and a Bayesian mixed-effects meta-regression tool, and included prevalence, deaths, years lived with disability (YLDs), and years of life lost (YLLs). All estimates were presented as counts, age-standardized rates per 100,000 people and percentage change, with 95% uncertainty intervals (UIs).Results: Worldwide, there were 1.80 million (95% UI 1.64–1.98) cases of MC, 1.62 million (95% UI 1.37–1.90) cases of AC and 4.21 million (95% UI 3.63–4.87) cases of OC, contributing to 46,486 (95% UI 39,709–51,824), 88,890 (95% UI 80,935–96,290), and 233,159 (95% UI 213,677–248,289) deaths in 2017, respectively. Furthermore, globally, there were 131,376 (95% UI 90,113–183,001) YLDs and 1.26 million (95% UI 1.10–1.42) YLLs attributable to MC, 139,087 (95% UI 95,134–196,130) YLDs and 2.84 million (95% UI 2.60–3.07) YLLs attributable to AC, and 353,325 (95% UI 237,907–493,908) YLDs and 5.51 million (95% UI 4.95–5.99) YLLs attributable to OC in 2017. At the national level, the age-standardized prevalence rates varied by 10.4 times for MC, 252.6 times for AC and 38.1 times for OC; the age-standardized death rates varied by 43.9 times for MC, 531.0 times for AC and 43.3 times for OC; the age-standardized YLD rates varied by 12.4 times for MC, 223.7 times for AC, and 34.1 times for OC; and the age-standardized YLL rates varied by 38.4 times for MC, 684.8 times for AC, and 36.2 times for OC. Between 1990 and 2017, despite the decreases in age-standardized rates, the global numbers of prevalent cases, deaths, YLDs, and YLLs have increased for all the diseases.Conclusion: Accurate assessment of the burden of MC, AC, and OC is essential for formulating effective preventative prevention and treatment programs and optimizing health system resource allocation. Our results suggest that MC, AC, and OC remain important global public health problems with increasing numbers of prevalent cases, deaths, YLDs, and YLLs over the past decades, and there are significant geographic variations in the burden of these diseases. Further research is warranted to expand our knowledge of potential risk factors and to improve the prevention, early detection and treatment of these diseases.
- 11 February 2021
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 8
Open AccessGlobal, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990–2017
Objective: To estimate the burden of myocarditis (MC), alcoholic cardiomyopathy (AC), and other cardiomyopathy (OC) for 195 countries and territories from 1990 to 2017.Methods: We collected detailed information on MC, AC, and OC between 1990 and 2017 from the Global Burden of Disease study 2017, which was designed to provide a systematic assessment of health loss due to diseases and injuries in 21 regions, covering 195 countries and territories. Estimates of MC, AC, and OC burden were produced using a standard Cause of Death Ensemble model and a Bayesian mixed-effects meta-regression tool, and included prevalence, deaths, years lived with disability (YLDs), and years of life lost (YLLs). All estimates were presented as counts, age-standardized rates per 100,000 people and percentage change, with 95% uncertainty intervals (UIs).Results: Worldwide, there were 1.80 million (95% UI 1.64–1.98) cases of MC, 1.62 million (95% UI 1.37–1.90) cases of AC and 4.21 million (95% UI 3.63–4.87) cases of OC, contributing to 46,486 (95% UI 39,709–51,824), 88,890 (95% UI 80,935–96,290), and 233,159 (95% UI 213,677–248,289) deaths in 2017, respectively. Furthermore, globally, there were 131,376 (95% UI 90,113–183,001) YLDs and 1.26 million (95% UI 1.10–1.42) YLLs attributable to MC, 139,087 (95% UI 95,134–196,130) YLDs and 2.84 million (95% UI 2.60–3.07) YLLs attributable to AC, and 353,325 (95% UI 237,907–493,908) YLDs and 5.51 million (95% UI 4.95–5.99) YLLs attributable to OC in 2017. At the national level, the age-standardized prevalence rates varied by 10.4 times for MC, 252.6 times for AC and 38.1 times for OC; the age-standardized death rates varied by 43.9 times for MC, 531.0 times for AC and 43.3 times for OC; the age-standardized YLD rates varied by 12.4 times for MC, 223.7 times for AC, and 34.1 times for OC; and the age-standardized YLL rates varied by 38.4 times for MC, 684.8 times for AC, and 36.2 times for OC. Between 1990 and 2017, despite the decreases in age-standardized rates, the global numbers of prevalent cases, deaths, YLDs, and YLLs have increased for all the diseases.Conclusion: Accurate assessment of the burden of MC, AC, and OC is essential for formulating effective preventative prevention and treatment programs and optimizing health system resource allocation. Our results suggest that MC, AC, and OC remain important global public health problems with increasing numbers of prevalent cases, deaths, YLDs, and YLLs over the past decades, and there are significant geographic variations in the burden of these diseases. Further research is warranted to expand our knowledge of potential risk factors and to improve the prevention, early detection and treatment of these diseases.
- 1 October 2020
- Published by Elsevier in Sleep Health
- Vol. 6 (5) , 657-661
Associations of sleep problems with health-risk behaviors and psychological well-being among Canadian adults
- 1 October 2020
- Published by Elsevier in Sleep Health
- Vol. 6 (5) , 657-661
Associations of sleep problems with health-risk behaviors and psychological well-being among Canadian adults
- Open Access
Global, regional, and national burden of myocarditis and cardiomyopathy, 1990-2017
Background: To estimate the burden of myocarditis (MC) and cardiomyopathy for 195 countries and territories from 1990 to 2017. Methods: We collected detailed information on MC and cardiomyopathy between 1990 and 2017 from the Global Burden of Disease study (GBD) 2017. Cardiomyopathy was divided into two types in GBD 2017, including alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC). All estimates were presented as counts, age-standardised rates per 100 000 people and percentage change, with 95% uncertainty intervals (UIs). Results: Worldwide, there were 1.80 million (95% UI 1.64 to 1.98) cases of MC, 1.62 million (95% UI 1.37 to 1.90) cases of AC and 4.21 million (95% UI 3.63 to 4.87) cases of OC, contributing to 46 486 (95% UI 39 709 to 51 824), 88 890 (95% UI 80 935 to 96 290) and 233 159 (95% UI 213 677 to 248 289) deaths in 2017, respectively. At the national level, the age-standardised prevalence rates varied by 10.4 times for MC, 252.6 times for AC and 38.1 times for OC; and the age-standardised death rates varied by 43.9 times for MC, 531.0 times for AC and 43.3 times for OC. Between 1990 and 2017, despite the decreases in age-standardised rates, the global numbers of prevalent cases and deaths have significantly increased for all the diseases. Females had greater decreases in age-standardised prevalence and death rates than males for all the diseases. Conclusions: MC, AC and OC remain important global public health problems, and there are significant geographic variations in the burden for all these diseases. More effective and geo-specific strategies are necessary to counteract and mitigate the future burden of these diseases. Key questions: What is already known?: ➢ Myocarditis (MC), alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC) impose a substantial economic burden on healthcare systems. Studies that have systematically assessed the global, regional, and national burden of these diseases are still scarce. What are the new findings?: ➢ Globally, there were an estimated 1.80 million (95% uncertainty interval (UI) 1.64 to 1.98) cases of MC, 1.62 million (95% UI 1.37 to 1.90) cases of AC and 4.21 million (95% UI 3.63 to 4.87) cases of OC in 2017. ➢ The global numbers of deaths due to MC, AC, and OC in 2017 were 46 486 (95% UI 39 709 to 51 824), 88 890 (95% UI 80 935 to 96 290) and 233 159 (95% UI 213 677 to 248 289), respectively. ➢ Across 21 world regions, the highest age-standardised prevalence rates of MC, AC and OC were seen in High-income Asia Pacific, Eastern Europe and Southern Sub-Saharan Africa, respectively. While the highest age-standardised death rates of MC, AC and OC were seen in Oceania, Eastern Europe and Central Europe, respectively. ➢ Despite the decreases in age-standardised rates, the global numbers of prevalent cases and deaths of MC, AC and OC have significantly increased between 1990 and 2017. What do the new findings imply?: ➢ Our findings suggested that total numbers of prevalent cases and deaths of MC, AC and OC are increasing worldwide. More effective and geo-specific strategies aimed at counteracting and mitigating the future burden of these diseases are warranted.
Open AccessGlobal, regional, and national burden of myocarditis and cardiomyopathy, 1990-2017
Background: To estimate the burden of myocarditis (MC) and cardiomyopathy for 195 countries and territories from 1990 to 2017. Methods: We collected detailed information on MC and cardiomyopathy between 1990 and 2017 from the Global Burden of Disease study (GBD) 2017. Cardiomyopathy was divided into two types in GBD 2017, including alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC). All estimates were presented as counts, age-standardised rates per 100 000 people and percentage change, with 95% uncertainty intervals (UIs). Results: Worldwide, there were 1.80 million (95% UI 1.64 to 1.98) cases of MC, 1.62 million (95% UI 1.37 to 1.90) cases of AC and 4.21 million (95% UI 3.63 to 4.87) cases of OC, contributing to 46 486 (95% UI 39 709 to 51 824), 88 890 (95% UI 80 935 to 96 290) and 233 159 (95% UI 213 677 to 248 289) deaths in 2017, respectively. At the national level, the age-standardised prevalence rates varied by 10.4 times for MC, 252.6 times for AC and 38.1 times for OC; and the age-standardised death rates varied by 43.9 times for MC, 531.0 times for AC and 43.3 times for OC. Between 1990 and 2017, despite the decreases in age-standardised rates, the global numbers of prevalent cases and deaths have significantly increased for all the diseases. Females had greater decreases in age-standardised prevalence and death rates than males for all the diseases. Conclusions: MC, AC and OC remain important global public health problems, and there are significant geographic variations in the burden for all these diseases. More effective and geo-specific strategies are necessary to counteract and mitigate the future burden of these diseases. Key questions: What is already known?: ➢ Myocarditis (MC), alcoholic cardiomyopathy (AC) and other cardiomyopathy (OC) impose a substantial economic burden on healthcare systems. Studies that have systematically assessed the global, regional, and national burden of these diseases are still scarce. What are the new findings?: ➢ Globally, there were an estimated 1.80 million (95% uncertainty interval (UI) 1.64 to 1.98) cases of MC, 1.62 million (95% UI 1.37 to 1.90) cases of AC and 4.21 million (95% UI 3.63 to 4.87) cases of OC in 2017. ➢ The global numbers of deaths due to MC, AC, and OC in 2017 were 46 486 (95% UI 39 709 to 51 824), 88 890 (95% UI 80 935 to 96 290) and 233 159 (95% UI 213 677 to 248 289), respectively. ➢ Across 21 world regions, the highest age-standardised prevalence rates of MC, AC and OC were seen in High-income Asia Pacific, Eastern Europe and Southern Sub-Saharan Africa, respectively. While the highest age-standardised death rates of MC, AC and OC were seen in Oceania, Eastern Europe and Central Europe, respectively. ➢ Despite the decreases in age-standardised rates, the global numbers of prevalent cases and deaths of MC, AC and OC have significantly increased between 1990 and 2017. What do the new findings imply?: ➢ Our findings suggested that total numbers of prevalent cases and deaths of MC, AC and OC are increasing worldwide. More effective and geo-specific strategies aimed at counteracting and mitigating the future burden of these diseases are warranted.
- Top Cited PapersOpen Access
- 31 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 7 (6) , 574-582
Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017
Aims: To estimate the prevalence, incidence, mortality, and risk factors for atrial fibrillation (AF) in 195 countries and territories from 1990 to 2017. Methods and results: Following the methodologies used in the Global Burden of Disease Study 2017, the prevalence, incidence, and mortality of AF were analysed by age, sex, year, socio-demographic index (SDI), and location. The percentage contributions of major risk factors to age-standardized AF deaths were measured by population attributable fractions. In 2017, there were 37.57 million [95% uncertainty interval (UI) 32.55–42.59] prevalent cases and 3.05 million (95% UI 2.61–3.51) incident cases of AF globally, contributing to 287 241 (95% UI 276 355–304 759) deaths. The age-standardized rates of prevalent cases, incident cases, and deaths of AF in 2017 and their temporal trends from 1990 to 2017 varied significantly by SDI quintile and location. High systolic blood pressure was the leading risk factor for AF age-standardized deaths [34.3% (95% UI 27.4–41.5)] in 2017, followed by high body mass index [20.7% (95% UI 11.5–32.2)] and alcohol use [9.4% (95% UI 7.0–12.2)]. Conclusion: Our study has systematically and globally assessed the temporal trends of AF, which remains a major public heath challenge. Although AF mainly occurred in developed countries, the unfavourable trend in countries with lower SDI also deserves particular attention. More effective prevention and treatment strategies aimed at counteracting the increase in AF burden should be established in some countries.
- 31 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 7 (6) , 574-582
Top Cited PapersOpen AccessGlobal, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017
Aims: To estimate the prevalence, incidence, mortality, and risk factors for atrial fibrillation (AF) in 195 countries and territories from 1990 to 2017. Methods and results: Following the methodologies used in the Global Burden of Disease Study 2017, the prevalence, incidence, and mortality of AF were analysed by age, sex, year, socio-demographic index (SDI), and location. The percentage contributions of major risk factors to age-standardized AF deaths were measured by population attributable fractions. In 2017, there were 37.57 million [95% uncertainty interval (UI) 32.55–42.59] prevalent cases and 3.05 million (95% UI 2.61–3.51) incident cases of AF globally, contributing to 287 241 (95% UI 276 355–304 759) deaths. The age-standardized rates of prevalent cases, incident cases, and deaths of AF in 2017 and their temporal trends from 1990 to 2017 varied significantly by SDI quintile and location. High systolic blood pressure was the leading risk factor for AF age-standardized deaths [34.3% (95% UI 27.4–41.5)] in 2017, followed by high body mass index [20.7% (95% UI 11.5–32.2)] and alcohol use [9.4% (95% UI 7.0–12.2)]. Conclusion: Our study has systematically and globally assessed the temporal trends of AF, which remains a major public heath challenge. Although AF mainly occurred in developed countries, the unfavourable trend in countries with lower SDI also deserves particular attention. More effective prevention and treatment strategies aimed at counteracting the increase in AF burden should be established in some countries.
- Open Access
- 27 August 2019
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (2) , 466-474
Distinct developmental trajectories of body mass index and diabetes risk: A 5‐year longitudinal study of Chinese adults
Aims/Introduction: This longitudinal study aimed to explore whether distinct developmental trajectories of body mass index (BMI) would be predictive of diabetes risk in general Chinese adults.Materials and Methods: A total of 4,519 participants aged >18 years who were free of diabetes in 2011 (baseline of the current analysis) were enrolled in this study. All participants completed a medical examination every year during 2011–2016, and BMI levels were measured two to six (average 5.6) times. Group‐based trajectory modeling was applied to identify BMI trajectories over time. New‐onset diabetes was confirmed in 2016.Results: During 2011–2016, four distinct BMI trajectories were identified according to BMI range and changing pattern over time: “low” (19.6%), “moderate” (33.4%), “moderate‐high” (33.4%) and “high” (13.6%). A total of 168 (3.7%) new‐onset diabetes cases were confirmed in 2016. Compared with the “low” BMI trajectory, participants in the “high” BMI trajectory were at significantly higher risk for new‐onset diabetes (adjusted relative risk 3.24, 95% confidence interval 1.27–8.24). Notably, BMI trajectories based on the first four or three annual BMI tests yielded similar results. By contrast, no significant correlation was found between categories of baseline BMI and new‐onset diabetes in 2016 after multivariate adjustment.Conclusions: The present results show that distinct BMI trajectories, even identified using just four or three annual BMI tests, are significantly associated with new‐onset diabetes. Monitoring BMI trajectories over time might provide an important approach to identify subpopulations at higher risk for developing diabetes.
- 27 August 2019
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (2) , 466-474
Open AccessDistinct developmental trajectories of body mass index and diabetes risk: A 5‐year longitudinal study of Chinese adults
Aims/Introduction: This longitudinal study aimed to explore whether distinct developmental trajectories of body mass index (BMI) would be predictive of diabetes risk in general Chinese adults.Materials and Methods: A total of 4,519 participants aged >18 years who were free of diabetes in 2011 (baseline of the current analysis) were enrolled in this study. All participants completed a medical examination every year during 2011–2016, and BMI levels were measured two to six (average 5.6) times. Group‐based trajectory modeling was applied to identify BMI trajectories over time. New‐onset diabetes was confirmed in 2016.Results: During 2011–2016, four distinct BMI trajectories were identified according to BMI range and changing pattern over time: “low” (19.6%), “moderate” (33.4%), “moderate‐high” (33.4%) and “high” (13.6%). A total of 168 (3.7%) new‐onset diabetes cases were confirmed in 2016. Compared with the “low” BMI trajectory, participants in the “high” BMI trajectory were at significantly higher risk for new‐onset diabetes (adjusted relative risk 3.24, 95% confidence interval 1.27–8.24). Notably, BMI trajectories based on the first four or three annual BMI tests yielded similar results. By contrast, no significant correlation was found between categories of baseline BMI and new‐onset diabetes in 2016 after multivariate adjustment.Conclusions: The present results show that distinct BMI trajectories, even identified using just four or three annual BMI tests, are significantly associated with new‐onset diabetes. Monitoring BMI trajectories over time might provide an important approach to identify subpopulations at higher risk for developing diabetes.
- Open Access
- 1 August 2017
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 14 (1) , 1-9
Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults
Non-alcoholic fatty liver disease (NAFLD), recognized as the liver manifestation of metabolic syndrome, is highly prevalent in the general population. Recent studies suggest that lipid accumulation product is significantly associated with metabolic abnormalities. The aim of this study was to assess the accuracy of lipid accumulation product (LAP) as an effective screening tool for diagnosing NAFLD in the general population. A total of 40,459 subjects aged ≥18 years were enrolled in this cross-sectional study. LAP was calculated as [waist circumference (cm) – 65] × triglyceride concentration (mmol//L) in men and [waist circumference (cm) – 58] × triglyceride concentration (mmol/L) in women. Multiple logistic regression and receiver operating characteristic (ROC) analyses were performed. According to multiple logistic regression analyses, LAP was significantly associated with a higher prevalence and severity of NAFLD in both men and women. When assessed using ROC curve analyses, LAP exhibited high diagnostic accuracy for identifying NAFLD, and the areas under the curves (AUC) in men and women were 0.843 (95% CI 0.837, 0.849) and 0.887 (95% CI 0.882, 0.892), respectively. After further analyzed in different age groups, the diagnostic accuracy of LAP was found to be significantly better in younger age groups (aged 18-34 for men; aged 18-34 and 35-44 years for women) for both sexes. LAP is significantly associated with the presence and severity of NAFLD, and has a high diagnostic accuracy for identifying NAFLD in the general population. The diagnostic accuracy of LAP was especially high among younger age groups.
- 1 August 2017
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 14 (1) , 1-9
Open AccessLipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults
Non-alcoholic fatty liver disease (NAFLD), recognized as the liver manifestation of metabolic syndrome, is highly prevalent in the general population. Recent studies suggest that lipid accumulation product is significantly associated with metabolic abnormalities. The aim of this study was to assess the accuracy of lipid accumulation product (LAP) as an effective screening tool for diagnosing NAFLD in the general population. A total of 40,459 subjects aged ≥18 years were enrolled in this cross-sectional study. LAP was calculated as [waist circumference (cm) – 65] × triglyceride concentration (mmol//L) in men and [waist circumference (cm) – 58] × triglyceride concentration (mmol/L) in women. Multiple logistic regression and receiver operating characteristic (ROC) analyses were performed. According to multiple logistic regression analyses, LAP was significantly associated with a higher prevalence and severity of NAFLD in both men and women. When assessed using ROC curve analyses, LAP exhibited high diagnostic accuracy for identifying NAFLD, and the areas under the curves (AUC) in men and women were 0.843 (95% CI 0.837, 0.849) and 0.887 (95% CI 0.882, 0.892), respectively. After further analyzed in different age groups, the diagnostic accuracy of LAP was found to be significantly better in younger age groups (aged 18-34 for men; aged 18-34 and 35-44 years for women) for both sexes. LAP is significantly associated with the presence and severity of NAFLD, and has a high diagnostic accuracy for identifying NAFLD in the general population. The diagnostic accuracy of LAP was especially high among younger age groups.
- Open Access
- 12 December 2016
- Published by Springer Nature in Nutrition Journal
- Vol. 15 (1) , 1-7
Association between homocysteine and non-alcoholic fatty liver disease in Chinese adults: a cross-sectional study
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and its prevalence is likely to rise even further. To help understand the pathogenesis and early prevention of progressive NAFLD, this large-scale study was designed to explore the potential association between homocysteine and the prevalence of NAFLD. A total of 7203 subjects aged 18 years or older were enrolled in this cross-sectional study. The association of homocysteine with the prevalence of NAFLD, in the total sample and stratified by subgroups, was examined using multiple logistic regression analyses. Subjects in the higher quartiles of homocysteine had a higher prevalence of NAFLD. After multivariate adjustment, the odds ratio (OR) for NAFLD in the highest compared with the lowest quartile of homocysteine was 2.08 (95% confidence interval [CI] 1.61, 2.67). Moreover, in the subgroup analyses, we found an effect modification by gender, body mass index (BMI) and smoking status on the association between homocysteine and the prevalence of NAFLD (P for interaction: 0.001, 0.002 and <0.001, respectively). A stronger association was observed in female, obese and non-smoking adults than in male, normal weight and smoking subjects. Homocysteine was significantly associated with the prevalence of NAFLD, particularly in female, obese or non-smoking adults.
- 12 December 2016
- Published by Springer Nature in Nutrition Journal
- Vol. 15 (1) , 1-7
Open AccessAssociation between homocysteine and non-alcoholic fatty liver disease in Chinese adults: a cross-sectional study
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and its prevalence is likely to rise even further. To help understand the pathogenesis and early prevention of progressive NAFLD, this large-scale study was designed to explore the potential association between homocysteine and the prevalence of NAFLD. A total of 7203 subjects aged 18 years or older were enrolled in this cross-sectional study. The association of homocysteine with the prevalence of NAFLD, in the total sample and stratified by subgroups, was examined using multiple logistic regression analyses. Subjects in the higher quartiles of homocysteine had a higher prevalence of NAFLD. After multivariate adjustment, the odds ratio (OR) for NAFLD in the highest compared with the lowest quartile of homocysteine was 2.08 (95% confidence interval [CI] 1.61, 2.67). Moreover, in the subgroup analyses, we found an effect modification by gender, body mass index (BMI) and smoking status on the association between homocysteine and the prevalence of NAFLD (P for interaction: 0.001, 0.002 and <0.001, respectively). A stronger association was observed in female, obese and non-smoking adults than in male, normal weight and smoking subjects. Homocysteine was significantly associated with the prevalence of NAFLD, particularly in female, obese or non-smoking adults.